FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118201145> ?p ?o ?g. }

• W3118201145 endingPage "1325" @default.
• W3118201145 startingPage "1315" @default.
• W3118201145 abstract "Attenuated psychosis syndrome (APS), a condition for further study in the Diagnostic and Statistical Manual of Mental Disorders-5, comprises psychotic symptoms that are qualitatively similar to those observed in schizophrenia but are less severe. Patients with APS are at high risk of converting to first-episode psychosis (FEP). As evidence for effective pharmacological interventions in APS is limited, novel treatments may provide symptomatic relief and delay/prevent psychotic conversion. This trial aims to investigate the efficacy, safety, and tolerability of BI 409306, a potent and selective phosphodiesterase-9 inhibitor, versus placebo in APS. Novel biomarkers of psychosis are being investigated.In this Phase II, multinational, double-blind, parallel-group trial, randomized (1:1) patients will receive BI 409306 50 mg or placebo twice daily for 52 weeks. Patients (n = 300) will be enrolled to determine time to remission of APS, time to FEP, change in everyday functional capacity (Schizophrenia Cognition Rating Scale), and change from baseline in Brief Assessment of Cognition composite score and Positive and Negative Syndrome Scale scores. Potential biomarkers of psychosis under investigation include functional measures of brain activity and automated speech analyses. Safety is being assessed throughout.This trial will determine whether BI 409306 is superior to placebo in achieving sustainable remission of APS and improvements in cognition and functional capacity. These advances may provide evidence-based treatment options for symptomatic relief in APS. Furthermore, the study will assess the effect of BI 409306 on psychotic conversion and explore the identification of patients at risk for conversion using novel biomarkers." @default.
• W3118201145 created "2021-01-05" @default.
• W3118201145 creator A5004272477 @default.
• W3118201145 creator A5004754581 @default.
• W3118201145 creator A5018920191 @default.
• W3118201145 creator A5026643447 @default.
• W3118201145 creator A5034988511 @default.
• W3118201145 creator A5045984988 @default.
• W3118201145 creator A5063649965 @default.
• W3118201145 creator A5073531380 @default.
• W3118201145 creator A5073856751 @default.
• W3118201145 creator A5074947929 @default.
• W3118201145 creator A5077759727 @default.
• W3118201145 creator A5090423513 @default.
• W3118201145 date "2020-12-22" @default.
• W3118201145 modified "2023-10-14" @default.
• W3118201145 title "A randomized Phase <scp>II</scp> trial evaluating efficacy, safety, and tolerability of oral <scp>BI</scp> 409306 in attenuated psychosis syndrome: Design and rationale" @default.
• W3118201145 cites W1267646904 @default.
• W3118201145 cites W1508413454 @default.
• W3118201145 cites W1718572743 @default.
• W3118201145 cites W1933775912 @default.
• W3118201145 cites W1985642065 @default.
• W3118201145 cites W1990043440 @default.
• W3118201145 cites W1993889588 @default.
• W3118201145 cites W2024654275 @default.
• W3118201145 cites W2050000904 @default.
• W3118201145 cites W2053347807 @default.
• W3118201145 cites W2057646365 @default.
• W3118201145 cites W2058831047 @default.
• W3118201145 cites W2074477232 @default.
• W3118201145 cites W2082733297 @default.
• W3118201145 cites W2085626359 @default.
• W3118201145 cites W2101845848 @default.
• W3118201145 cites W2112957597 @default.
• W3118201145 cites W2121366540 @default.
• W3118201145 cites W2140606211 @default.
• W3118201145 cites W2140824803 @default.
• W3118201145 cites W2144107861 @default.
• W3118201145 cites W2166663076 @default.
• W3118201145 cites W2166933135 @default.
• W3118201145 cites W2170371870 @default.
• W3118201145 cites W2198559820 @default.
• W3118201145 cites W2198642455 @default.
• W3118201145 cites W2202104541 @default.
• W3118201145 cites W2255138985 @default.
• W3118201145 cites W2339096596 @default.
• W3118201145 cites W2418826885 @default.
• W3118201145 cites W2466076674 @default.
• W3118201145 cites W2466834759 @default.
• W3118201145 cites W2523547844 @default.
• W3118201145 cites W2535067734 @default.
• W3118201145 cites W2551638625 @default.
• W3118201145 cites W2559603325 @default.
• W3118201145 cites W2560311853 @default.
• W3118201145 cites W2569627086 @default.
• W3118201145 cites W2579907512 @default.
• W3118201145 cites W2587918810 @default.
• W3118201145 cites W2603643132 @default.
• W3118201145 cites W2765822046 @default.
• W3118201145 cites W2790178001 @default.
• W3118201145 cites W2795252372 @default.
• W3118201145 cites W2805985567 @default.
• W3118201145 cites W2989821710 @default.
• W3118201145 cites W2996145273 @default.
• W3118201145 cites W3118201145 @default.
• W3118201145 cites W4210963505 @default.
• W3118201145 cites W4247665917 @default.
• W3118201145 cites W4292528167 @default.
• W3118201145 cites W96109483 @default.
• W3118201145 doi "https://doi.org/10.1111/eip.13083" @default.
• W3118201145 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8451588" @default.
• W3118201145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33354862" @default.
• W3118201145 hasPublicationYear "2020" @default.
• W3118201145 type Work @default.
• W3118201145 sameAs 3118201145 @default.
• W3118201145 citedByCount "8" @default.
• W3118201145 countsByYear W31182011452018 @default.
• W3118201145 countsByYear W31182011452019 @default.
• W3118201145 countsByYear W31182011452020 @default.
• W3118201145 countsByYear W31182011452022 @default.
• W3118201145 countsByYear W31182011452023 @default.
• W3118201145 crossrefType "journal-article" @default.
• W3118201145 hasAuthorship W3118201145A5004272477 @default.
• W3118201145 hasAuthorship W3118201145A5004754581 @default.
• W3118201145 hasAuthorship W3118201145A5018920191 @default.
• W3118201145 hasAuthorship W3118201145A5026643447 @default.
• W3118201145 hasAuthorship W3118201145A5034988511 @default.
• W3118201145 hasAuthorship W3118201145A5045984988 @default.
• W3118201145 hasAuthorship W3118201145A5063649965 @default.
• W3118201145 hasAuthorship W3118201145A5073531380 @default.
• W3118201145 hasAuthorship W3118201145A5073856751 @default.
• W3118201145 hasAuthorship W3118201145A5074947929 @default.
• W3118201145 hasAuthorship W3118201145A5077759727 @default.
• W3118201145 hasAuthorship W3118201145A5090423513 @default.
• W3118201145 hasBestOaLocation W31182011451 @default.
• W3118201145 hasConcept C118552586 @default.
• W3118201145 hasConcept C126322002 @default.
• W3118201145 hasConcept C142724271 @default.

• next